GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Cytogen Inc (XKRX:217330) » Definitions » EV-to-FCF

Cytogen (XKRX:217330) EV-to-FCF : -16.57 (As of May. 25, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Cytogen EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Cytogen's Enterprise Value is ₩169,324 Mil. Cytogen's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was ₩-10,216 Mil. Therefore, Cytogen's EV-to-FCF for today is -16.57.

The historical rank and industry rank for Cytogen's EV-to-FCF or its related term are showing as below:

XKRX:217330' s EV-to-FCF Range Over the Past 10 Years
Min: -190.46   Med: -29.71   Max: -0.44
Current: -17.4

During the past 11 years, the highest EV-to-FCF of Cytogen was -0.44. The lowest was -190.46. And the median was -29.71.

XKRX:217330's EV-to-FCF is ranked worse than
100% of 94 companies
in the Medical Diagnostics & Research industry
Industry Median: 25.03 vs XKRX:217330: -17.40

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-25), Cytogen's stock price is ₩9300.00. Cytogen's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was ₩-774.131. Therefore, Cytogen's PE Ratio for today is At Loss.


Cytogen EV-to-FCF Historical Data

The historical data trend for Cytogen's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cytogen EV-to-FCF Chart

Cytogen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -14.55 -46.81 -47.86 -41.69 -25.75

Cytogen Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -32.79 -30.67 -30.41 -25.75 -49.17

Competitive Comparison of Cytogen's EV-to-FCF

For the Diagnostics & Research subindustry, Cytogen's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cytogen's EV-to-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Cytogen's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Cytogen's EV-to-FCF falls into.



Cytogen EV-to-FCF Calculation

Cytogen's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=169324.029/-10216.087
=-16.57

Cytogen's current Enterprise Value is ₩169,324 Mil.
Cytogen's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-10,216 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cytogen  (XKRX:217330) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Cytogen's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=9300.00/-774.131
=At Loss

Cytogen's share price for today is ₩9300.00.
Cytogen's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-774.131.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Cytogen EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Cytogen's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Cytogen (XKRX:217330) Business Description

Traded in Other Exchanges
N/A
Address
128, Beobwon-ro, Songpa-gu, A-8 Floor, SK V1 GL Metrocity, Seoul, KOR, 05854
Cytogen Inc is a Korea based company engaged in developing HD Microporous chip using microfluidics and nanotechnology and it captures viable CTCS (circulating tumor cells) from cancer patients blood. The firm operates in two business areas including Liquid Biopsy Applications and Liquid Biopsy Platforms.

Cytogen (XKRX:217330) Headlines

No Headlines